-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Category Archives: Public Policy
Latest From Public Policy
Legislative Hopes, Fears
Biotechnology advances are poised now more than ever to help policymakers achieve their goals of supporting innovation in health care, renewable energy, and green technologies. How can they help us? Here are our six hopes (and one big concern) for the term ahead. HOPE 1: Cultivate an atmosphere for patient access to our products While the Congress considers finding savings, do it in a way that does not threaten patient access to drug products by Read More >
Patent Utility Requirements for Biopharmaceutical Inventions: How Much is Enough?
A debate between the innovative and generic perspectives on pharmaceutical patent law in Canada, moderated by David Kappos, will be held in Chicago on Monday April 22nd from 2:30-3:30pm in room S404A at this year’s BIO International Convention. Former Undersecretary of Commerce for Intellectual Property and USPTO Director David J. Kappos will moderate a panel of legal experts who will discuss recent developments in the area of patent utility and its implications for biopharmaceutical innovation. Read More >
BIO Members Receive Patents for Humanity Award
The United States Patent and Trademark Office announced the winners of the Patents for Humanity awards. “The Patents for Humanity is a competition recognizing patent owners and licensees who address global challenges in health and standards of living.” The USPTO website provides this background on the BIO member winners: “Gilead Sciences “Of the 35 million people worldwide suffering from HIV, 95% live in developing countries. Gilead produces antiretroviral therapies for the treatment of HIV. They Read More >
Patent and Tech Transfer Sessions at 2013 BIO International Convention
Patent and Technology Transfer sessions feature prominently at the 2013 BIO International Convention in Chicago from April 22-25, 2013. Topics cover developing patent and tech transfer issues in the U.S. and internationally. Many of the sessions provide Continuing Legal Education (CLE) and Registered Technology Transfer Professional (RTTP) credits. The Biotech Patenting and Technology Transfer Track sessions are below: Behind the Tech Transfer Headlines: What are You Missing? Headline-making news reports of multiyear, multimillion dollar strategic Read More >
Kirtsaeng v. John Wiley & Sons: No Good Deed Goes Unpunished
The Supreme Court handed Kirtsaeng a victory last week finding his importation and resale of copyrighted books exhausted the copyright under the First Sale Doctrine. In a vain attempt at corporate responsibility, the publishers in this case created two versions of textbooks; a no-frills “Asia edition” to sell at affordable prices to students in less affluent places like Thailand, and a higher quality more expensive version to relatively more affluent students in places like the Read More >
